The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.

President Trump announced a deal with Eli Lilly and Novo Nordisk to lower prices on hugely popular weight-loss drugs for Medicare, Medicaid and American patients who pay with their own money.

President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to reduce prices for their obesity ...

The list prices of obesity drugs Wegovy and Zepbound are over $1,000, but that's not necessarily what you pay.

WASHINGTON (AP) — President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand ...

Eli Lilly and Novo Nordisk will lower prices for GLP-1 drugs, aligning with new drug pricing initiatives and Medicare Part D pilot coverage starting April 2026. Lilly's Zepbound and orforglipron will ...

US President Donald Trump has announced deals that aim to lower the cost of popular weight-loss drugs, as pharmaceutical prices take centre stage in his administration's messaging around affordability ...

President Donald Trump has  unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy. The drugs are part ...

Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...

The White House announced reduced pricing for the popular weight-loss drugs made by Eli Lilly and Novo Nordisk.